Compare OCSL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | GERN |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 821.1M |
| IPO Year | 2007 | N/A |
| Metric | OCSL | GERN |
|---|---|---|
| Price | $11.75 | $1.26 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $12.63 | $2.17 |
| AVG Volume (30 Days) | 750.9K | ★ 14.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $0.31 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $1.04 |
| 52 Week High | $14.77 | $2.01 |
| Indicator | OCSL | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 32.94 |
| Support Level | $10.88 | $1.24 |
| Resistance Level | $13.19 | $1.29 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 11.89 | 10.42 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.